Prelude Therapeutics Inc financial data

Symbol
PRLD on Nasdaq
Industry
Pharmaceutical Preparations
Location
175 Innovation Boulevard, Wilmington, DE
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.08K % -2.91%
Debt-to-equity 16 % +48.8%
Return On Equity -59.8 % -8.9%
Return On Assets -51.6 % -3.95%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55M shares +0.39%
Entity Public Float 77.1M USD +18.1%
Weighted Average Number of Shares Outstanding, Basic 75.8M shares +34.7%
Weighted Average Number of Shares Outstanding, Diluted 75.8M shares +34.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 114M USD +18.8%
General and Administrative Expense 28.8M USD -3.32%
Operating Income (Loss) -142M USD -13.5%
Net Income (Loss) Attributable to Parent -130M USD -11.2%
Earnings Per Share, Basic -1.78 USD/shares +24.3%
Earnings Per Share, Diluted -1.78 USD/shares +24.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 27.8M USD +5.23%
Marketable Securities, Current 152M USD -33.5%
Assets, Current 183M USD -29.8%
Property, Plant and Equipment, Net 7.55M USD +24.2%
Operating Lease, Right-of-Use Asset 29.6M USD +3122%
Assets 224M USD -20.1%
Accounts Payable, Current 6.17M USD +10.5%
Employee-related Liabilities, Current 5.64M USD +11.8%
Accrued Liabilities, Current 11.4M USD +31.8%
Liabilities, Current 23.3M USD +53.6%
Operating Lease, Liability, Noncurrent 15.5M USD
Other Liabilities, Noncurrent 3.22M USD -4.34%
Liabilities 42M USD +126%
Accumulated Other Comprehensive Income (Loss), Net of Tax -290K USD +59.2%
Retained Earnings (Accumulated Deficit) -523M USD -33.1%
Stockholders' Equity Attributable to Parent 182M USD -30.4%
Liabilities and Equity 224M USD -20.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.8M USD -5.5%
Net Cash Provided by (Used in) Financing Activities -269K USD -101%
Net Cash Provided by (Used in) Investing Activities 31.2M USD +73.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -584K USD +95.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.9M USD +4.53%
Deferred Tax Assets, Valuation Allowance 148M USD +32.9%
Deferred Tax Assets, Gross 153M USD +36.7%
Operating Lease, Liability 17.7M USD
Payments to Acquire Property, Plant, and Equipment 289K USD -64.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -129M USD -12.4%
Lessee, Operating Lease, Liability, to be Paid 42.7M USD
Property, Plant and Equipment, Gross 10.9M USD +32.4%
Operating Lease, Liability, Current 2.23M USD +138%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.98M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.75M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 25M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.05M USD
Deferred Tax Assets, Operating Loss Carryforwards 72M USD +8.92%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.13M USD
Operating Lease, Payments 0 USD -100%
Depreciation, Depletion and Amortization 426K USD +53.2%
Deferred Tax Assets, Net of Valuation Allowance 5.01M USD +773%
Share-based Payment Arrangement, Expense 24.3M USD -3.97%